Fundz

Inversago Pharma Raises $95 Million Cad In Series C Financing

PRIVATEOct 17, 2022

Amount Raised

$95 Million

Round Type

Series C

MontrealBiotechnologyHealth Care

Description

Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”). Additional new investors Forbion’s Growth Opportunities Fund (“Forbion Growth”) and Amgen Ventures joined current investors including Forbion’s Ventures Fund IV (“Forbion Ventures”), Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations in the financing round.

Quick answer

Inversago Pharma raised $95 Million in a Series C round, dated October 17, 2022. Inversago Pharma is based in Montreal, Quebec, Canada.

How much did Inversago Pharma raise?
Inversago Pharma raised $95 Million in a Series C round on October 17, 2022.
What does Inversago Pharma do?
Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class,..
Where is Inversago Pharma based and how big is it?
Inversago Pharma is based in Montreal, Quebec, Canada.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Inversago Pharma that raised within 45 days of this round, from Fundz verified event records.

  • Superior Biologics raised $136M (Funding Round) on December 1, 2022.
  • Carrick raised an undisclosed amount (Series C) on December 1, 2022.
  • RE-VANA THERAPEUTICS raised $12M (Series A) on November 30, 2022.
  • iECURE raised $65M (Funding Round) on November 30, 2022.
  • Experic raised $14M (Series B) on November 30, 2022.
  • Nox Health raised an undisclosed amount (Corporate Round) on November 30, 2022.

Who to call at Inversago Pharma, and when

A new round usually means Inversago Pharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Inversago Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inversago Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inversago Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Inversago Pharma

Location

Montreal, Quebec, Canada

About

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Inversago Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Inversago Pharma's next move

See what Strategic adds

Inversago Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.